PolyPid

PolyPid Ltd. operates as a phase 3 biopharma company. Its proprietary PLEX technology pairs with medications, enables precise delivery of drugs at effective release rates, over pre-determined durations ranging from several days to months. The firm's product candidates are designed to address unmet medical needs by delivering active pharmaceutical ingredients, or APIs, locally at predetermined release rates and durations over extended periods ranging from days to several months. The company was founded by Noam Emanuel in 2008 and is headquartered in Petach Tikva, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

PolyPid advances SHIELD II trial, secures financing for growth

PolyPid's Q2 2024 earnings call showcased progress in the SHIELD II trial and financial resilience through secured financing.
Strong leadership appointments and positive feedback on D-PLEX100's potential highlight the company's strategic strengths.
While facing timeline risks and financial challenges, PolyPid remains focused on advancing D-PLEX100 and seizing growth opportunities.
Overall, PolyPid's performance reflects a balanced approach to innovation, financial management, and commitment to achieving key milestones.

PolyPid advances SHIELD II trial with positive outlook amid financial challenges

PolyPid's Q3 2024 earnings call highlighted progress in SHIELD II trial, financial position, and challenges with increased R&D expenses. The company's focus on advancing clinical trials and managing expenses while exploring growth opportunities is key for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PolyPid Ltd. operates as a phase 3 biopharma company. Its proprietary PLEX technology pairs with medications, enables precise delivery of drugs at effective release rates, over pre-determined durations ranging from several days to months. The firm's product candidates are designed to address unmet medical needs by delivering active pharmaceutical ingredients, or APIs, locally at predetermined release rates and durations over extended periods ranging from days to several months. The company was founded by Noam Emanuel on February 28, 2008 and is headquartered in Petach Tikva, Israel.

PETAH TIKVA, Israel, Nov. 24, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that D-PLEX100 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the prevention of surgical site infections (SSIs) in patients undergoing elective colorectal surgery.

PolyPid Granted Breakthrough Therapy Designation from FDA for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Colorectal Surgery

PolyPid Ltd. (PYPD) CEO Amir Weisberg on Q3 2020 Results - Earnings Call Transcript

•  Over 50% of p lanned 60 centers for ongoing Phase 3 SHIELD I t rial of D-PLEX 100 in a bdominal s urgery have r eceived IRB approval 

PolyPid Ltd. Provides Corporate Update and Reports Third Quarter 2020 Financial Results

PETAH TIKVA, Israel, Nov. 04, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will present at two investor conferences in November. Details on the presentations can be found below. The company will also participate in one-on-one investor meetings at the AGP Virtual Healthcare Symposium 2020 on Thursday, November 19.

PolyPid to Participate in Three Upcoming Investor Conferences

PETAH TIKVA, Israel, Oct. 28, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will report its third quarter 2020 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 11, 2020. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

PolyPid to Report Third Quarter 2020 Financial Results and Operational Highlights on November 11, 2020

PolyPid Ltd. (PYPD) CEO Amir Weisberg on Q2 2020 Results - Earnings Call Transcript

Initiated Phase 3 SHIELD I Trial for D-PLEX100 in Abdominal Surgery and Received Fast Track Designation for D-PLEX100  from FDA

PolyPid Ltd. Provides Corporate Update and Reports Second Quarter 2020 Financial Results

PETAH TIKVA, Israel, Aug.  05, 2020  (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will report its second quarter 2020 financial results and operational highlights before the Nasdaq market opens on Wednesday, August 19, 2020. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

PolyPid to Report Second Quarter 2020 Financial Results and Operational Highlights on August 19, 2020

PETAH TIKVA, Israel, Aug.  03, 2020  (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that D-PLEX100 has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the prevention of post abdominal surgery incisional infections.

PolyPid Granted Fast Track Designation from FDA for D-PLEX₁₀₀ for Prevention of Surgical Site Infections in Abdominal Surgery

PETAH TIKVA, Israel, July  27, 2020  (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that Dr. Anthony Senagore, colorectal surgeon and a medical advisor to PolyPid, is presenting a recorded video presentation today highlighting previously presented key results from PolyPid’s successfully completed Phase 2 clinical trial of D-PLEX100 for the prevention of surgical site infections in abdominal surgery at the American Society of Colon and Rectal Surgeons (A.S.C.R.S.) 2020 Annual Scientific Conference Recorded Sessions.

PolyPid to Present Phase 2 Results of D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Surgery at the American Society of Colon and Rectal Surgeons 2020 Annual Scientific Conference Recorded Sessions

Polypid starts phase 3 trial in prevention of post-abdominal surgery incisional infection.

PolyPid Phase 3 And Other News: The Good, Bad And Ugly Of Biopharma

PolyPid  disclosed Monday that it set terms for its initial public offering, in which the Israel-based biopharmaceutical company expects to raise up to $53.1 million. The company is offering 3.125 million shares in the IPO, which is expected to price between $15 and $17 a share.

PolyPid sets IPO terms, could be valued at up to $279 million

News for PolyPid Stock (PYPD)